CD30 positive systemic anaplastic large cell lymphoma - brentuximab vedotin - initial authority application form (PB123)

Use this form to apply for initial PBS-subsidised treatment with brentuximab vedotin for patients with CD30 positive systemic anaplastic large cell lymphoma.

Page last updated: 17 June 2024.
QC 20686